EP2066638A1 - Procédé de purification du montélukast - Google Patents
Procédé de purification du montélukastInfo
- Publication number
- EP2066638A1 EP2066638A1 EP07788278A EP07788278A EP2066638A1 EP 2066638 A1 EP2066638 A1 EP 2066638A1 EP 07788278 A EP07788278 A EP 07788278A EP 07788278 A EP07788278 A EP 07788278A EP 2066638 A1 EP2066638 A1 EP 2066638A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- montelukast
- process according
- purification process
- comprised
- aqueous phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Definitions
- the present invention relates to a process for the preparation of highly pure Montelukast.
- it relates to a purification process of Montelukast by selective extractions of Montelukast or its impurities in a mixture of an organic solvent and water.
- Montelukast is the International Non-proprietary Name (INN) of 1 -[[[(1 R)-1 -[3- [(1 E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1 -hydroxy-1 - methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid, and CAS No. 158966-92-8.
- INN International Non-proprietary Name
- Montelukast sodium salt (CAS No 151767-02-1 ) is currently used in treatment of asthma, inflammation, angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection.
- EP 480.717 discloses certain substituted quinolone compounds including Montelukast sodium salt, methods for their preparation, and pharmaceutical compositions using these compounds.
- Several preparation processes of Montelukast sodium salt are reported in this document.
- Example 161 relates to the preparation of Montelukast sodium salt.
- preparation of Montelukast sodium salt proceeds through its corresponding methyl ester, whose preparation comprises sodium hydride or cesium carbonate assisted coupling of methyl-1 - (mercaptomethyl)-cyclopropaneacetate with the protected mesylate (2-(2-(2- (3(S)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3- (methanesulfonyloxy)propyl)phenyl)-2-propoxy)tetrahydropyran, generated in situ.
- the methyl ester thus obtained is hydrolyzed to the Montelukast acid which is then converted directly to the sodium salt.
- Montelukast and its pharmaceutically acceptable salts are obtained by complex synthetic procedures which cause the formation of several by-products due to competing side reactions. These processes need tedious workups to isolate the Montelukast and its intermediates and thus results in excess time cycle, which in turn rendering the process more costly and less eco friendly. It is known that the purification of Montelukast is laborious and complex, being difficult to achieve a Montelukast with a high degree of purity since Montelukast and its precursors are unstable to oxygen and light causing a fast degradation. For the above reasons, Montelukast is generally obtained with a low degree of chemical and optical purity.
- EP 737.186 relates to a process for the preparation of Montelukast or its salts thereof, which comprises reacting the dilithium dianion of 1 -(mercaptomethyl)-cyclopropane- acetic acid with the corresponding mesylate alcohol ((2-(2-(2-(3(S)-(3-(2-(7- chloro-2-quinolinyl)-ethenyl)phenyl)-3-(methanesulfonyloxy)-propyl)phenyl)- 2-propanol), to obtain Montelukast.
- Patent application US 2005/234241 also describes a process for the preparation of Montelukast which occurs via the formation of organic Montelukast base salts.
- example 2 describes the formation of the tert-butylamine salt of Montelukast.
- Patent application WO 06/008751 also describes a process for the preparation of Montelukast and a process for its purification via the formation of several organic Montelukast base salts.
- Montelukast sodium can be purified by obtaining montelukast free acid as a solid and converting the montelukast free acid into montelukast sodium.
- Montelukast which proceeds with high yield and which allows to obtain Montelukast with high chemical purity.
- the process is based on carrying out a specific set of solvent extractions at specific ranges of pH and temperature which depends on the type of impurities to remove.
- Montelukast can be purified by an easily industrializable process, which is simple and cost-effective, does not use toxic solvents and do not involve significant waste of product.
- a process for the purification of Montelukast, or pharmaceutically salts thereof, or solvates thereof, including stereoisomers or mixtures thereof which comprises carrying out a specific set of selective extractions of Montelukast or its impurities, in a mixture of an organic solvent and water, at specific ranges of pH and temperature, said set of solvent extractions comprising at least one wash of an aqueous phase containing crude Montelukast in salt form with an organic solvent, at a pH comprised between 12.0 and 13.5 and at a temperature comprised between 10 0 C and about 5 0 C below the boiling point of the mixture.
- the process of the present invention allows to purify some specific impurities derived of this process which are very difficult to purify by other known methods.
- the purification process of the present invention can be used to purify Montelukast prepared according to any known process of the prior art.
- the process for the purification of Montelukast of formula (I), or its pharmaceutically acceptable salts, or its solvates, including stereoisomers or mixtures thereof comprises carrying out a specific set of selective extractions of Montelukast or its impurities, in a mixture of an organic solvent and water.
- the impurities that may be effectively removed with the purification process of the present invention are the following ones.
- the purification process is especially useful to purify Montelukast obtained from the corresponding cyano intermediate of formula (II) mentioned above.
- the specific impurities derived of this process may be effectively removed with the solvent extractions of the aqueous phase containing Montelukast in salt form, at a pH comprised between 12.0 and 13.5.
- these impurities are the cyano compound used as starting material and the following impurities:
- the purification process further comprises a previous step where a compound of formula (II), CN
- Montelukast crude of formula (I) in form of salt is reacted with an inorganic base in a mixture of an (d-C 6 )-alcohol and water, to give Montelukast crude of formula (I) in form of salt.
- the alcohol may be separated, for instance, by distillation.
- an organic solvent and water can be added to the crude of the reaction in order to separate an aqueous phase containing the salts from the organic phase containing the Montelukast in salt form.
- the Montelukast in salt form can be extracted of the organic phase with water.
- To the resulting aqueous solution containing the Montelukast in salt form is carried out the purification process of the present invention.
- the purification process of the present invention can also be carried out from an aqueous solution containing the Montelukast in salt form previously obtained by adding to a mixture of Montelukast acid in an organic solvent, an aqueous solution of a base.
- the purification process comprises the following steps: (a) carrying out at least one wash of an aqueous phase containing crude Montelukast in salt form with an organic solvent, at a pH comprised between 12.0 and 13.5 and at a temperature comprised between 10 0 C and about 5 0 C below the boiling point of the mixture and separating the aqueous phase containing the Montelukast in salt form; (b) optionally, carrying out one or more washes of the aqueous phase of step (a) with an organic solvent at a pH comprised between 8.5 and 10.0 and at a temperature comprised between 10 0 C and about 5 0 C below the boiling point of the mixture, and separating the aqueous phase containing the Montelukast in salt form; (c) carrying out an extraction of the purified Montelukast from the aqueous phase of steps (a) or (b) with an organic solvent at a pH comprised between 4.5 and 8.0 and at a temperature comprised between 10
- the organic solvent used in the purification process is selected from the group consisting of (C 2 -C 8 )- ether, (C 6 -C 8 )-aromatic hydrocarbon, (Ci-C 3 )-chlorine containing solvents and mixtures thereof. More preferably, the solvent is selected from toluene, tert-butyl methyl ether, tetrahydrofuran, and mixtures thereof.
- two or three washes at a pH comprised between 12.0 and 13.5 are carried out.
- said washes of step (a) are carried out at a pH comprised between 12.0 and 13.5 and at a temperature comprised between 20 and 6O 0 C. More, preferably, at least two washes are carried out at set pH and temperature.
- the washes of step (b) are carried out at a pH comprised between 9.0 and 9.5 and at a temperature comprised between 20 and 6O 0 C.
- the most appropriate temperature conditions vary depending mainly on the solvent used. The temperature can be readily determined by the skilled person in the art with the help of the teaching of the examples given in the description.
- the Montelukast is isolated from the organic phase of step (c) as acid, for instance, by filtration, and optionally, is treated with a base in the presence of an appropriate solvent to form the corresponding pharmaceutically acceptable salt of Montelukast, which is isolated from the reaction medium, for instance, by filtration.
- the Montelukast is isolated from the organic phase of step (c) in salt form by adding a base and isolating from the reaction medium the corresponding pharmaceutically acceptable salt of Montelukast, for instance, by filtration.
- the preparation of purified Montelukast by the process of the present invention involves an important improvement over the known processes.
- the advantageous features of the purification process of the present invention the following can be mentioned: (i) it allows to purify Montelukast from several impurities that are difficult to purify by known methods; (ii) it is able to purify Montelukast crude with a low degree of purity and achieving a high yield; and (iii) the Montelukast is manipulated during all the process in solution up to its isolation in solid form as acid or as a salt, so that repeatedly recrystallizations of Montelukast are avoided.
- the solvent was distilled off under vacuum (Purity by HPLC: 61.5 area %; impurity i 2 : 1.84 area %; impurity i 5 : 3.70 area %; impurity i 6 : 1.42 area %).
- the mixture was partitioned with 1000 ml of toluene and 1500 ml of water at room temperature.
- the aqueous phase dissolved the inorganic salts was discarded.
- the organic phase was mixed with 1500 ml of water and the mixture was heated to 60 0 C and stirred for 15 minutes. At this point the product was dissolved in the aqueous layer.
- the pH of the aqueous layer was 12.5. Some impurities from the process were dissolved in the organic layer.
- the toluene solution obtained in the previous example was stirred at room temperature for 12 hours. After this period of time, a yellow suspension was formed. The outcome solid was filtered off, washed with toluene and dried under vacuum at 30 0 C for 24 hours. 53 g of Montelukast acid were recovered (Purity by HPLC: 96 area %). Yield: 90%.
- aqueous solution was acidified to pH 9.3 with an aqueous 2M solution of acetic acid and washed twice with 30 ml of toluene. Both extractions were carried out at 60 0 C. Finally, another 30 ml of toluene were added to the aqueous solution and the mixture was acidified to pH 6.0 with an aqueous 2M solution of acetic acid at room temperature. The final organic layer was separated and kept as a solution of purified Montelukast acid. (Purity by HPLC: 96.8 area %; impurity i 2 : 0.02 area %; impurity i 3 : 1.23 area
- Example 4 Purification of Montelukast acid using tert-butyl mehtyl ether as solvent for the extractions
- the final organic layer was separated and kept as a solution of purified Montelukast acid (Purity by HPLC: 97.7 area %; impurity i 2 :not detected; impurity i 3 : 1.11 area %; impurity i 5 : not detected; impurity i 6 : not detected). Yield: 67%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Quinoline Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07788278A EP2066638B8 (fr) | 2006-08-09 | 2007-08-07 | Procédé de purification du montélukast |
PL07788278T PL2066638T3 (pl) | 2006-08-09 | 2007-08-07 | Sposób oczyszczania Montelukastu |
SI200730588T SI2066638T1 (sl) | 2006-08-09 | 2007-08-07 | Postopek za čiščenje montelukasta |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83687306P | 2006-08-09 | 2006-08-09 | |
EP06118689A EP1886997A1 (fr) | 2006-08-09 | 2006-08-09 | Procédé de purification de montelukast |
PCT/EP2007/058176 WO2008017667A1 (fr) | 2006-08-09 | 2007-08-07 | Procédé de purification du montélukast |
EP07788278A EP2066638B8 (fr) | 2006-08-09 | 2007-08-07 | Procédé de purification du montélukast |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2066638A1 true EP2066638A1 (fr) | 2009-06-10 |
EP2066638B1 EP2066638B1 (fr) | 2011-02-23 |
EP2066638B8 EP2066638B8 (fr) | 2011-10-12 |
Family
ID=37667497
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06118689A Withdrawn EP1886997A1 (fr) | 2006-08-09 | 2006-08-09 | Procédé de purification de montelukast |
EP07788278A Active EP2066638B8 (fr) | 2006-08-09 | 2007-08-07 | Procédé de purification du montélukast |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06118689A Withdrawn EP1886997A1 (fr) | 2006-08-09 | 2006-08-09 | Procédé de purification de montelukast |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100029945A1 (fr) |
EP (2) | EP1886997A1 (fr) |
JP (1) | JP2010500324A (fr) |
KR (1) | KR20090037445A (fr) |
CN (1) | CN101490005B (fr) |
AT (1) | ATE499345T1 (fr) |
AU (1) | AU2007283613A1 (fr) |
CA (1) | CA2657017A1 (fr) |
DE (1) | DE602007012728D1 (fr) |
ES (1) | ES2361239T3 (fr) |
HR (1) | HRP20110322T1 (fr) |
IL (1) | IL195622A (fr) |
MX (1) | MX2008015135A (fr) |
NO (1) | NO20090748L (fr) |
PL (1) | PL2066638T3 (fr) |
PT (1) | PT2066638E (fr) |
RU (1) | RU2009108271A (fr) |
SI (1) | SI2066638T1 (fr) |
WO (1) | WO2008017667A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2925145A1 (fr) | 2003-07-07 | 2005-01-13 | Insurance Services Office, Inc. | Systeme d'information routiere |
ES2358923T3 (es) | 2005-07-05 | 2011-05-16 | Teva Pharmaceutical Industries, Ltd. | Purificación de montelukast. |
EP2552892A1 (fr) | 2010-03-31 | 2013-02-06 | KRKA, D.D., Novo Mesto | Synthèse efficace pour la préparation de montélukast et nouvelle forme cristalline d'intermédiaires dans celle-ci |
JP5553096B2 (ja) * | 2012-08-29 | 2014-07-16 | 大日本印刷株式会社 | 高純度モンテルカストの製造法 |
CN103570619B (zh) * | 2013-11-08 | 2015-12-09 | 南京靖龙药物研发有限公司 | 一种孟鲁司特钠衍生物的制备方法 |
CN105646344B (zh) * | 2016-02-29 | 2018-08-14 | 山东新时代药业有限公司 | 一种孟鲁司特的纯化方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107612A1 (en) * | 2002-12-30 | 2005-05-19 | Dr. Reddy's Laboratories Limited | Process for preparation of montelukast and its salts |
CA2554572A1 (fr) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries Ltd. | Polymorphes d'acide sans montelukast |
EP1711166A1 (fr) * | 2004-02-03 | 2006-10-18 | Chemagis Ltd. | Formes amorphes stables de montelukast sodique |
US7189853B2 (en) * | 2004-04-15 | 2007-03-13 | Dr. Reddy's Laboratories Limited | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts |
WO2006058545A1 (fr) * | 2004-11-30 | 2006-06-08 | Medichem, S.A. | Nouveau procede de preparation d'un antagoniste de leucotriene |
WO2006064269A2 (fr) * | 2004-12-17 | 2006-06-22 | Cipla Limited | Sels d'antagoniste de leukotriene |
-
2006
- 2006-08-09 EP EP06118689A patent/EP1886997A1/fr not_active Withdrawn
-
2007
- 2007-08-07 JP JP2009523275A patent/JP2010500324A/ja active Pending
- 2007-08-07 CN CN2007800263787A patent/CN101490005B/zh not_active Expired - Fee Related
- 2007-08-07 WO PCT/EP2007/058176 patent/WO2008017667A1/fr active Application Filing
- 2007-08-07 DE DE602007012728T patent/DE602007012728D1/de active Active
- 2007-08-07 CA CA002657017A patent/CA2657017A1/fr not_active Abandoned
- 2007-08-07 AU AU2007283613A patent/AU2007283613A1/en not_active Abandoned
- 2007-08-07 US US12/376,773 patent/US20100029945A1/en not_active Abandoned
- 2007-08-07 AT AT07788278T patent/ATE499345T1/de not_active IP Right Cessation
- 2007-08-07 RU RU2009108271/04A patent/RU2009108271A/ru not_active Application Discontinuation
- 2007-08-07 ES ES07788278T patent/ES2361239T3/es active Active
- 2007-08-07 KR KR1020097002300A patent/KR20090037445A/ko not_active Application Discontinuation
- 2007-08-07 PL PL07788278T patent/PL2066638T3/pl unknown
- 2007-08-07 MX MX2008015135A patent/MX2008015135A/es active IP Right Grant
- 2007-08-07 EP EP07788278A patent/EP2066638B8/fr active Active
- 2007-08-07 SI SI200730588T patent/SI2066638T1/sl unknown
- 2007-08-07 PT PT07788278T patent/PT2066638E/pt unknown
-
2008
- 2008-12-01 IL IL195622A patent/IL195622A/en not_active IP Right Cessation
-
2009
- 2009-02-17 NO NO20090748A patent/NO20090748L/no not_active Application Discontinuation
-
2011
- 2011-05-03 HR HR20110322T patent/HRP20110322T1/hr unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2008017667A1 * |
Also Published As
Publication number | Publication date |
---|---|
IL195622A0 (en) | 2009-09-01 |
EP2066638B1 (fr) | 2011-02-23 |
DE602007012728D1 (de) | 2011-04-07 |
EP1886997A1 (fr) | 2008-02-13 |
SI2066638T1 (sl) | 2011-06-30 |
CN101490005A (zh) | 2009-07-22 |
AU2007283613A1 (en) | 2008-02-14 |
CN101490005B (zh) | 2011-08-31 |
JP2010500324A (ja) | 2010-01-07 |
PT2066638E (pt) | 2011-05-16 |
ES2361239T3 (es) | 2011-06-15 |
NO20090748L (no) | 2009-03-09 |
WO2008017667A1 (fr) | 2008-02-14 |
ATE499345T1 (de) | 2011-03-15 |
AU2007283613A8 (en) | 2009-01-22 |
KR20090037445A (ko) | 2009-04-15 |
MX2008015135A (es) | 2008-12-15 |
EP2066638B8 (fr) | 2011-10-12 |
US20100029945A1 (en) | 2010-02-04 |
IL195622A (en) | 2011-03-31 |
CA2657017A1 (fr) | 2008-02-14 |
HRP20110322T1 (hr) | 2011-06-30 |
PL2066638T3 (pl) | 2011-07-29 |
RU2009108271A (ru) | 2010-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5188501B2 (ja) | モンテルカストおよびそのアミン塩類の精製方法 | |
US5523477A (en) | Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid | |
EP2066638B1 (fr) | Procédé de purification du montélukast | |
CZ187896A3 (en) | Process for preparing chemical compound, the chemical compound per se, dicyclohexylamine salt thereof and process for preparing such salt | |
EP2195295B1 (fr) | Procédé de fabrication d'acide montélukast dans un milieu liquide ionique | |
WO2008015703A2 (fr) | Procédé pour la préparation de montelukast et de ses sels | |
EP2185517B1 (fr) | Procédé de préparation d'un antagoniste des leucotriènes et d'un intermédiaire de celui-ci | |
JP6059157B2 (ja) | モンテルカスト中間体のカンファースルホン酸塩 | |
KR100920314B1 (ko) | 몬테루카스트 신규한 염 및 그의 제조방법 | |
JP5553096B2 (ja) | 高純度モンテルカストの製造法 | |
WO2011004298A1 (fr) | Montélukast à l'état hexaméthylène-diamine, et son utilisation pour l'élaboration de montélukast sodique | |
KR101323664B1 (ko) | 몬테루카스트 제조방법과 이를 위한 중간체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090309 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602007012728 Country of ref document: DE Date of ref document: 20110407 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007012728 Country of ref document: DE Effective date: 20110407 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAX | Requested extension states of the european patent have changed |
Extension state: RS Payment date: 20090309 Extension state: HR Payment date: 20090309 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20110322 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20110509 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2361239 Country of ref document: ES Kind code of ref document: T3 Effective date: 20110615 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20110223 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20110322 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20110322 Country of ref document: HR Payment date: 20110715 Year of fee payment: 5 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20110223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110524 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110523 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E011121 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20110811 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20110719 Year of fee payment: 5 Ref country code: DE Payment date: 20110728 Year of fee payment: 5 Ref country code: ES Payment date: 20110822 Year of fee payment: 5 Ref country code: HU Payment date: 20110727 Year of fee payment: 5 Ref country code: GB Payment date: 20110819 Year of fee payment: 5 Ref country code: TR Payment date: 20110718 Year of fee payment: 5 Ref country code: PT Payment date: 20110719 Year of fee payment: 5 Ref country code: FR Payment date: 20110817 Year of fee payment: 5 Ref country code: PL Payment date: 20110718 Year of fee payment: 5 Ref country code: SI Payment date: 20110715 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20110817 Year of fee payment: 5 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20111124 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007012728 Country of ref document: DE Effective date: 20111124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110831 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110831 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: PBON Ref document number: P20110322 Country of ref document: HR Effective date: 20120808 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20130207 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120807 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120807 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120808 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20130311 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130430 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120807 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110807 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120808 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120807 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110223 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120807 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120831 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007012728 Country of ref document: DE Effective date: 20130301 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20131022 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120807 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: LAPE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120807 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120808 |